Semaglutide

Safety of Semaglutide.

Smits MM, et al. · Frontiers in endocrinology · 2021

Clinical Pharmacokinetics of Semaglutide: A Systematic Review.

Yang XD, et al. · Drug design, development and therapy · 2024

Wegovy (semaglutide): a new weight loss drug for chronic weight management.

Singh G, et al. · Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.

Bikou A, et al. · Expert opinion on pharmacotherapy · 2024

Semaglutide: First Global Approval.

Dhillon S · Drugs · 2018

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Sorli C, et al. · The lancet. Diabetes & endocrinology · 2017

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

Kadowaki T, et al. · The lancet. Diabetes & endocrinology · 2022

Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.

Li X, et al. · Redox biology · 2024

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.

Krüger N, et al. · JAMA · 2025

Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.

MacIsaac RJ · Future cardiology · 2025

As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.

Suran M · JAMA · 2023

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.

Friedrichsen M, et al. · Diabetes, obesity & metabolism · 2021